Avatrombopag is effective in patients with chemoradiotherapy-induced aplastic anemia: a single-center, retrospective study

Killick, 2016, Guidelines for the diagnosis and management of adult aplastic anaemia, Br J Haematol, 172, 187, 10.1111/bjh.13853 Peck-Radosavljevic, 2019, Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L-PLUS 2), Hepatology, 70, 1336, 10.1002/hep.30561 Georges, 2018, Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment, Blood Adv, 2, 2020, 10.1182/bloodadvances.2018021162 Townsley, 2017, Eltrombopag added to standard immunosuppression for aplastic anemia, N Engl J Med, 376, 1540, 10.1056/NEJMoa1613878 Babushok, 2022, Eltrombopag: a springboard to early responses in SAA, Blood, 139, 1, 10.1182/blood.2021014046 Patel, 2022, Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study, Blood, 139, 34, 10.1182/blood.2021012130 Desmond, 2014, Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug, Blood, 123, 1818, 10.1182/blood-2013-10-534743 Virk, 2021, Al-Samkari H. An evaluation of avatrombopag for the treatment of thrombocytopenia, Expert Opin Pharmacother, 22, 273, 10.1080/14656566.2020.1841748 Kuter, 2021, The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag, Blood Rev Peffault De Latour, 2022, Eltrombopag added to immunosuppression in severe aplastic anemia, N Engl J Med, 386, 11, 10.1056/NEJMoa2109965 Scheinberg, 2021, Acquired severe aplastic anaemia: how medical therapy evolved in the 20th and 21st centuries, Br J Haematol, 194, 954, 10.1111/bjh.17403 Scheinberg, 2018, Activity of eltrombopag in severe aplastic anemia, Blood Adv, 2, 3054, 10.1182/bloodadvances.2018020248 Kong, 2017, A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy, Blood, 130, 1097, 10.1182/blood-2017-01-761262 Terrault, 2014, Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure, J Hepatol, 61, 1253, 10.1016/j.jhep.2014.07.007 Kuter, 2018, Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies, Br J Haematol, 183, 466, 10.1111/bjh.15574 Bussel, 2014, A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia, Blood, 123, 3887, 10.1182/blood-2013-07-514398 Ghanima, 2019, Thrombopoietin receptor agonists: ten years later, Haematologica, 104, 1112, 10.3324/haematol.2018.212845 Ikeda, 2009, Development of thrombopoietin receptor agonists for clinical use, J Thromb Haemost, 7, 239, 10.1111/j.1538-7836.2009.03440.x Luby, 2008, AKR-501 activates the thrombopoietin receptor through interaction with the transmembrane domain, Blood, 112, 5391, 10.1182/blood.V112.11.5391.5391 Jurczak, 2018, Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia, Br J Haematol, 183, 479, 10.1111/bjh.15573 Fukushima-Shintani, 2009, AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist, Eur J Haematol, 82, 247, 10.1111/j.1600-0609.2008.01198.x Al-Samkari, 2019, Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia, Ther Adv Hematol, 10, 10.1177/2040620719841735 Markham, 2021, Avatrombopag: a review in thrombocytopenia, Drugs, 81, 1905, 10.1007/s40265-021-01613-y Sobi. FDA grants avatrombopag Orphan Drug Designation for the treatment of chemotherapy-induced thrombocytopenia. Available at: https://www.sobi.com/en/press-releases/fda-grants-avatrombopag-orphan-drug-designation-treatment-chemotherapy-induced. Accessed April 9, 2021. Al-Samkari, 2022, Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Haematol, 9, e179, 10.1016/S2352-3026(22)00001-1 Lozano, 2022, Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia, Lancet Haematol, 9, e168, 10.1016/S2352-3026(22)00030-8 Terrault, 2018, Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia, Gastroenterology, 155, 705, 10.1053/j.gastro.2018.05.025 Gao, 2022, Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors, Platelets, 33, 1024, 10.1080/09537104.2022.2026910 Winkler, 2019, Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag, Blood, 133, 2575, 10.1182/blood.2019000478 Fukushima-Shintani, 2008, AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis, Exp Hematol, 36, 1337, 10.1016/j.exphem.2008.04.020 Al-Samkari, 2021, A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies, Haematologica, 106, 1148, 10.3324/haematol.2020.251900 Fattizzo, 2019, Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation, Drugs, 79, 1305, 10.1007/s40265-019-01159-0 Glaxosmithkline. Promacta: prescribing information. Available at: https://www.novartis.us/sites/www.novartis.us/files/promacta.pdf. Accessed April 1, 2021. Jenkins, 2007, Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, Blood, 109, 4739, 10.1182/blood-2006-11-057968 Kumagai, 2007, Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study, J Clin Pharmacol, 47, 1489, 10.1177/0091270007306563 Erickson-Miller, 2009, Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist, Stem Cells, 27, 424, 10.1634/stemcells.2008-0366 Deng, 2021, Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial, Front Pharmacol, 12, 10.3389/fphar.2021.704093 Li, 2019, Efficacy and safety of avatrombopag in patients with thrombocytopenia: a systematic review and meta-analysis of randomized controlled trials, Front Pharmacol, 10, 829, 10.3389/fphar.2019.00829 Olnes, 2012, Eltrombopag and improved hematopoiesis in refractory aplastic anemia, N Engl J Med, 367, 11, 10.1056/NEJMoa1200931